24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
ABIRALIEVA 250MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | ABIRALIEVA 250MG |
|---|---|
| Composition | Abiraterone Acetate Tablets IP 25mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (120 tab) |
| Country of Origin | India |
ABIRALIEVA 250MG (Abiraterone Acetate Tablets IP 25mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
ABIRALIEVA 250 MG (Abiraterone Acetate Tablets IP 250 mg) is a prescription anticancer medicine containing Abiraterone Acetate 250 mg, a targeted hormonal therapy widely used in the treatment of advanced prostate cancer. It is specifically designed to help manage prostate cancers that depend on male hormones, known as androgens, for growth and survival.
Prostate cancer is one of the most common cancers affecting men worldwide. In many cases, cancer cells continue to grow even after conventional hormone-lowering treatments. ABIRALIEVA 250 MG helps address this challenge by reducing androgen production throughout the body, thereby slowing cancer progression and helping improve treatment outcomes.
Abiraterone Acetate belongs to a class of medicines called Androgen Biosynthesis Inhibitors. It works by blocking the activity of the CYP17 enzyme, which plays a crucial role in the production of testosterone and other androgens in the adrenal glands, testes, and prostate tumor tissues. By significantly reducing androgen levels, the medicine helps limit the growth and spread of prostate cancer cells.
Unlike traditional chemotherapy, which directly attacks rapidly dividing cells, Abiraterone targets hormone production pathways associated with cancer progression. This targeted mechanism has made it an important component of modern prostate cancer treatment strategies.
ABIRALIEVA 250 MG is commonly prescribed for:
The medicine is often used in combination with corticosteroids such as prednisone or prednisolone as recommended by healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ABIRALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy require regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted hormonal action, ABIRALIEVA 250 MG has become a trusted treatment option for advanced prostate cancer worldwide.
ABIRALIEVA 250 MG (Abiraterone Acetate Tablets IP 250 mg) is primarily used for the treatment and management of advanced prostate cancer.
The medicine is widely prescribed for patients whose cancer progresses despite androgen deprivation therapy.
Abiraterone may be used in combination treatment plans for metastatic hormone-sensitive disease.
The medicine helps manage advanced stages of prostate cancer.
Doctors may prescribe Abiraterone when prostate cancer returns after previous treatment.
The medicine is a key component of targeted hormonal treatment programs.
Abiraterone helps slow disease progression and maintain treatment response.
The medicine supports individualized cancer treatment strategies.
Abiraterone Acetate belongs to a class of medicines known as Androgen Biosynthesis Inhibitors.
ABIRALIEVA works by:
This targeted mechanism helps improve disease control and support long-term cancer management.
Like all medicines, ABIRALIEVA 250 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are commonly reported during treatment.
Some patients may experience elevated blood pressure levels.
Swelling in the feet, ankles, or legs may occur.
Musculoskeletal discomfort may develop during therapy.
The medicine may affect potassium balance in the body.
Episodes of warmth and sweating may occur.
Headaches may occasionally occur during treatment.
Nausea, indigestion, or abdominal discomfort may develop.
Regular monitoring may be required due to possible liver-related effects.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of ABIRALIEVA 250 MG (Abiraterone Acetate Tablets IP 250 mg) should always be determined by a qualified oncologist.
The severity and progression of prostate cancer influence treatment planning.
Doctors may adjust therapy according to effectiveness and patient tolerance.
Liver health plays an important role in dosage considerations.
Other medicines may influence treatment decisions.
Individual patient factors contribute to dosage recommendations.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant women should avoid contact with crushed or damaged tablets. The medicine should only be handled according to healthcare recommendations.
It is primarily used for the treatment of advanced and metastatic prostate cancer.
Abiraterone Acetate is a hormonal anticancer medicine that reduces androgen production to help control prostate cancer growth.
No. It is a targeted hormonal therapy and works differently from traditional chemotherapy.
Corticosteroids may help manage treatment-related effects and improve overall therapy outcomes.
Yes. Liver function changes may occur, which is why regular monitoring is recommended.
Yes. It works by reducing androgen production, including testosterone.
Yes. Blood tests, liver assessments, potassium monitoring, and blood pressure checks are important throughout therapy.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and prostate cancer treatment.